Pharma Focus Asia

Kyowa Kirin Invests US$530 million for New Biologics Manufacturing Plant in USA


Kyowa Kirin invests US$530 million to construct a state-of-the-art manufacturing facility in North Carolina, USA.


The 171,700-square-foot, two-reactor facility will accelerate the development and production of biologic therapies for patients with rare and serious diseases.

The new facility will manufacture innovative biologic therapies, including next-generation antibodies, for planned clinical trials and future commercial use while creating more resilient and efficient supply lines that more readily withstand shifting global forces.

The 75-acre campus will allow for future expansion if the portfolio necessitates greater capacity as pipeline programmes advance.

The new facility will draw on the expertise of these institutions and expand upon the recently introduced manufacturing methods and technologies in Takasaki, aiming to further boost manufacturing productivity and efficiency.

The new facility will be scalable with the Takasaki Plant in Japan to help ease technology transfer between the two plants and add production capacity. This will help accelerate drug development and production.

Construction of the facility is anticipated to start in the latter half of 2024, with full operations commencing in 2027.


Name      Kyowa Kirin
Type        New Construction
Budget   US$530 million
Year         2027

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference